James A. Geraghty - 12 Dec 2024 Form 4 Insider Report for PIERIS PHARMACEUTICALS, INC. (PVLA)

Reporting relationship: Director
Issuer ticker: PVLA
Reported as of: 12 Dec 2024
Net transaction value: -$0.01
SEC form: 4
Accepted by SEC: 12 Dec 2024, 16:16:43 UTC
Prior SEC filing: 28 Oct 2024
Next SEC filing: 04 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Thomas Bures, Attorney-in-Fact

Key filing fact

James A. Geraghty filed Form 4 for PIERIS PHARMACEUTICALS, INC. (PVLA) on 12 Dec 2024.

Key facts

This page summarizes James A. Geraghty's Form 4 filing for PIERIS PHARMACEUTICALS, INC. (PVLA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Dec 2024, 16:16.

Change

Previous filing in this sequence was filed on 28 Oct 2024.
Current net transaction value: -$0.01.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PIRS transaction

Series F Preferred Stock, par value $0.001 per share

Disposed to Issuer

Transaction value: $0.01
Shares: -1
Change %: -100%
Price: $0.0100
Shares after: 0
Date: 12 Dec 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This Form 4 relates to the redemption of the Series F Preferred Stock, par value $0.001, that was issued to James A. Geraghty on August 7, 2024. The Series F Preferred Stock was redeemed by Pieris Pharmaceuticals, Inc. for $0.01 automatically and effective immediately after the effectiveness of its Authorized Share Increase, as set forth in the Certificate of Designation of Series F Preferred Stock.